 trial cyclophosphamide doxorubicin vincristine versus cisplatin alternation regimens small-cell lung cancer Between April May study standard chemotherapy alternating basis patients small-cell lung cancer patients cyclophosphamide dose IV day doxorubicin IV day vincristine IV day CAV cisplatin IV day IV days PE PE CAV/PE regimen weeks patients study eligible analysis CAV PE CAV/PE response rates PE CAV/PE rate CAV complete response rates similar Nine patients initial CAV regimen contrast patients CAV PE regimen regimens non-cross-resistant response duration CAV/PE CAV survival time CAV/PE months superior CAV months PE months patients limited disease survival alternating arm superior survival CAV arm survival PE arm toxic effects acceptable chemotherapy regimens results chemotherapy standard chemotherapy CAV PE differences dramatic